MP010 (TME-DP)
MP010 (TME-DP)
종양미세환경을 직접 타깃하는
새로운 혁신 신약 차세대 TGF-β platform
종양미세환경 (Tumor Microenvironment, TME)
MP010의 작용 기전
First-in-Class 이중 기능성 TME 표적 트랩
높은 종양 특이적 친화도로 두 표적 모두에 효과적으로 결합하고 억제합니다.
종양 특이 단백질을 특이적으로 표적으로 삼아 전신 순환계로 인한 독성을 감소시킵니다.
CD8+ 세포와 NK 세포의 종양 내 침투를 유도합니다.
RNA 시퀀싱을 통해 TME 특이적 유전자 조절과 전신 면역 영향을 최소화하는 우수한 안전성 프로파일을 확인하여 표적 외 독성을 최소화하도록 설계되었습니다.
다양한 종양 모델에서 탁월한 효능
췌장암(PANC02, PKCY for KRASm), 유방암(4T1 as TNBC), 대장암(CT26 as cold tumor) 장기 항임 효과를 위한 강력한 T 세포 기억
종양 재투여 시 종양 성장은 관찰되지 않았습니다.
Mar, 2025
Tm4sf19 inhibition ameliorates inflammation and bone destruction in collagen-induced arthritis by suppressing TLR4-mediated inflammatory signaling and abnormal osteoclast activation
Bone ResearchNov, 2024
MIMERET, a Novel Mitochondrial-Targeted Drug, Improves Hepatic Steatosis by Stimulating Mitochondrial Fatty Acid Beta-Oxidation to Prevent Lipid Accumulation
AASLD 2024Nov, 2024
Vactosertib, a TGF-β signaling inhibitor, in combination with Durvalumab increased mOS in ≥2L treatment of patients with PD-L1-positive advanced NSCLC
SITC 2024Aug, 2024
The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial
Nature CommunicationsJul, 2024
Oral transforming growth factor-beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity
Cancer CommunicationsApr, 2024
Novel combination therapy for treating proteasome inhibitor-resistant multiple myeloma
AACR 2024Apr, 2024
Oral TGF-beta receptor1 inhibitor, Vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity
AACR 2024Feb, 2024
Clinical activity of transforming growth factor-β inhibitor vactosertib in combination 3 with imatinib in desmoid tumors: a multicenter phase Ib/II study
Clinical Cancer ResearchNov, 2023
A Competitive Inhibitor of MOART Showed Potent Therapeutic Effects in a Mouse Model of Collagen-induced Arthritis
미국류마티스학회 2023(ACR 2023)Oct, 2023
Efficacy and Safety of Vactosertib and Pembrolizumab Combination in Patients with Previously Treated Microsatellite Stable Metastatic Colorectal Cancer
유럽종양학회(ESMO)Apr, 2023
Vactosertib combined treatment with T1-44, a PRMT5 activity inhibitor, improves the survival and inhibits tumor invasion of murine pancreatic cancer model
American Association for Cancer Research 2023(AACR 2023)Feb, 2023
Combination treatment of T1-44, a PRMT5 inhibitor with Vactosertib, an inhibitor of TGF-β signaling, inhibits invasion and prolongs survival in a mouse model of pancreatic tumors
Cell Death and Disease (2023)Jan, 2023
Discovery of TRD-93 as a novel DRAK2 inhibitor
BULLETIN OF THE KOREAN CHEMICAL SOCIETYDec, 2022
MAST4 controls cell cycle in spermatogonial stem cells
Cell proliferation(IF : 8.755)Dec, 2022
Therapeutic Implications of TGF-β Pathway in Desmoid Tumor Based on Comprehensive Molecular Profiling and Clinicopathological Properties
CancersOct, 2022
ESRP1-regulated isoform switching of LRRFIP2 determines metastasis of gastric cance
Nature communicationSep, 2022
Phase 1b Study of Vactosertib in Combination with FOLFOX in Patients with Metastatic Pancreatic Ductal Adenocarcinoma who have Failed First-Line Gemcitabine/nab-Paclitaxel
미국암연구학회 췌장암 특별 컨퍼런스(AACR Special Conference on Pancreatic Cancer)2022Jan, 2022
Phase 1b Study of Vactosertib in Combination with nal-IRI plus 5FU/LV in Patients with Metastatic Pancreatic Ductal Adenocarcinoma who Failed First-Line Gemcitabine/nab-Paclitaxel
미국임상종양학회 위장관종양심포지엄(ASCO GI) 2022Nov, 2021
Tumor Microenvironment based on PD-L1 and CD8 T-cell infiltration correlated with the survival of MSS mCRC patients treated vactosertib in combination with pembrolizumab
미국 면역항암학회(SITC) 2021Nov, 2021
Spatial analysis of tumor-infiltrating lymphocytes correlates with the response of metastatic colorectal cancer patients treated with vactosertib in combination with pembrolizumab
미국 면역항암학회(SITC) 2021Jun, 2021
Efficacy and Safety of Vactosertib and Pembrolizumab Combination in Patients with Previously Treated Microsatellite Stable Metastatic Colorectal Cancer
미국임상종양학회(ASCO) 2021Jun, 2021
Phase 1b trial of Vactosertib in Combination with Pomalidomide in Relapsed Multiple Myeloma: A Corticosteroid-Free Approach by Targeting TGF-β Signaling Pathway
미국임상종양학회(ASCO) 2021Apr, 2021
BAG2 Promotes Tumorigenesis and Metastasis by Regulating the Cathepsin B Cleavage in Triple Negative Breast Cancer Cells
미국 암학회(AACR) 2021Apr, 2021
DRAK1 suppresses inflammation induced cervical cancer progression by targeting TRAF6 protein
미국 암학회 (AACR) 2021Apr, 2021
Beneficial effect of vactosertib combined with nal IRI5 FULV in pancreatic cancer treatment
미국 암학회 (AACR) 2021Apr, 2021
Genomic and transcriptomic analyses of desmoid tumor reveals enrichment of transforming growth factor beta responsive signature
미국 암학회 (AACR) 2021Nov, 2020
Vactosertib and Durvalumab as Second or Later Line Treatment for PD-L1 Positive Non-small Cell Lung Cancer: Interim Result
미국 면역항암학회 (SITC) 2020Sep, 2020
Safety and Efficacy of Vactosertib, a TGFBR1 Kinase Inhibitor, in Combination with Paclitaxel in Patients with Metastatic Gastric Adenocarcinoma
유럽종양학회 연례회의 (ESMO) Congress 2020May, 2020
A Phase 1 study of TGF-β inhibitor, Vactosertib, in combination with Imatinib in patients with advanced desmoid tumor (aggressive fibromatosis)
미국임상종양학회 (ASCO) 2020Nov, 2019
Safety and Preliminary clinical activity of Vactosertib, a selective TGF-β receptor I kinase inhibitor, in combination with Durvalumab in advanced Non-small cell lung cancer patients with low PD-L1 expression
미국면역암학회 (SITC) 2019Nov, 2019
Safety and preliminary clinical activity of Vactosertib, a selective TGF-β receptor I kinase inhibitor, in combination with Pembrolizumab in patients with metastatic colorectal or gastric cancer
미국면역암학회 (SITC) 2019Nov, 2019
TGF-β as a promising therapeutic target for treating Osteosarcoma
Innovation in AYA cancerJun, 2018
TGF-β Responsive signature is associated with anti-tumor effect of Vactosertib, a potent oral TGF-β receptor type1(TGFBRI) inhibitor in patients with advanced solid tumors
미국임상종양학회 (ASCO) 2018